Geode Capital Management, LLC Aligos Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 373,056 shares of ALGS stock, worth $220,103. This represents 0.0% of its overall portfolio holdings.

Number of Shares

373,056

Previous 321,044 16.2%

Holding current value

$220,103

Previous $211,000 72.99%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.64 - $1.13 $33,287 - $58,773	52,012 Added 16.2%	373,056 $365,000
Q4 2023 Feb 13, 2024	BUY	$0.56 - $0.8 $44,542 - $63,632	79,541 Added 32.94%	321,044 $211,000
Q3 2023 Nov 13, 2023	SELL	$0.71 - $1.06 $10,713 - $15,994	-15,089 Reduced 5.88%	241,503 $181,000
Q2 2023 Aug 11, 2023	BUY	$0.89 - $1.36 $50,493 - $77,158	56,734 Added 28.39%	256,592 $248,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $1.08 $8,401 - $10,195	9,440 Added 4.96%	199,858 $190,000

Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $170,943 - $351,749	-164,369 Reduced 46.33%	190,418 $230,000
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $10,838 - $63,574	5,211 Added 1.49%	354,787 $762,000
Q4 2021 Feb 11, 2022	BUY	$11.48 - $17.69 $412,373 - $635,442	35,921 Added 11.45%	349,576 $4.15 Million
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $849,532 - $1.03 Million	58,307 Added 22.83%	313,655 $4.86 Million
Q2 2021 Aug 13, 2021	BUY	$20.3 - $33.6 $1.55 Million - $2.57 Million	76,596 Added 42.85%	255,348 $5.21 Million
Q1 2021 May 12, 2021	BUY	$19.1 - $34.94 $1,107 - $2,026	58 Added 0.03%	178,752 $4.06 Million
Q4 2020 Feb 12, 2021	BUY	$13.2 - $32.74 $2.36 Million - $5.85 Million	178,694 New	178,694 $4.94 Million

Others Institutions Holding ALGS

# of Institutions

Shares Held

46.2M

Call Options Held

6.11M

Put Options Held

200

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $23.4M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Aligos Therapeutics, Inc. Transaction History